10-K - Avenue Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Avenue Therapeutics narrowed its net loss by 74.8% to -$2.9M from -$11.7M, driven by AJ201 return to AnnJi and Baergic divestiture that reduced development costs, while operating cash burn improved to -$1.8M from -$9.0M amid financing needs.

Key Takeaways

1Net cash used in operating activities fell to -$1.8M from -$9.0M, reflecting lower development expenses after AJ201 program changes and Baergic divestiture.

2Company evaluates market conditions and financing alternatives to enhance capital structure while planning continued SEC filings.

Key Financial Metrics

Net Income

-$2.9M

74.8%